The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 17, 2026

Filed:

Sep. 22, 2020
Applicant:

Fertin Pharma A/s, Vejle, DK;

Inventor:

Kent Albin Nielsen, Brande, DK;

Assignee:

Fertin Pharma A/S, Vejle, DK;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/465 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/045 (2006.01); A61K 31/05 (2006.01); A61K 31/125 (2006.01); A61K 31/16 (2006.01); A61K 31/167 (2006.01); A61K 36/45 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01); A61K 47/38 (2006.01); A61P 23/02 (2006.01);
U.S. Cl.
CPC ...
A61K 31/465 (2013.01); A61K 9/006 (2013.01); A61K 9/2072 (2013.01); A61K 31/045 (2013.01); A61K 31/05 (2013.01); A61K 31/125 (2013.01); A61K 31/16 (2013.01); A61K 31/167 (2013.01); A61K 36/45 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01); A61P 23/02 (2018.01);
Abstract

The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents, and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and/or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a third antagonist comprising (1R,2S,5R)—N-(4-Methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide (WS-12).


Find Patent Forward Citations

Loading…